Dear Colleagues,
MRC SUPREMO – a Phase III randomised trial to assess the role of adjuvant
chest wall irradiation in intermediate risk breast cancer after mastectomy.
Pathology QA Update
The whole QA exercise has been co-ordinated with military efficiency by Tammy
Piper in John Bartlett’s lab. It is well underway and the reviewing pathologists,
Jeremy Thomas and Andy Hanby, are up to date as we go to press. So far 550 cases
have been reviewed and there are a further 150 in the pipeline. We would like to
keep on top of this task to ensure that we get an accurate as possible measure of our
pathology data quality so please send us your blocks/slides promptly when asked.
Tissue Block Collection
Out of the 1113 patients recruited to date 876 have consented to donate tissue for
Trans-Supremo. The lab in Edinburgh has received 717 of these samples to date.
On the 27th of June the 600th sample was archived with the completion of the third
set of tissue-micro arrays – some 84% of samples received. However this is only
68% of the samples for all Trans-Supremo patients. Please therefore continue to
send any outstanding tissue samples to the laboratory.
China Monitoring & Patient Follow Up
HSBC Trustees has kindly awarded £68,140 from the Peter Chan Jee Yat
Foundation and the Yeung Ying & May Yeung Foundation in April 2011. This will be
used for the monitoring and follow up of patients in China for 10 years. As part of
their contractual obligations China are to recruit a maximum of 60 patients. Currently
they have recruited 58 patients so only need 2 more to reach their target.
We would like to congratulate the research teams at the following site for
randomising their first subject to the trial in June:



Dr Diana Ritchie, Claudia Turley and Emma Moody from the Victoria ACH,
Glasgow
Dr Amandeep Dhaddam, Dr Afaf Elhag, Alison Ames, Sarah Kent, Anne
Nunn, Tracey Hawkes & Damon Foster from Scarborough General Hospital
Dr Rema Jyothirmayi, Dr Charlotte Abson, Dr Russell Burcombe, Dr Andrew
Visioli, Dr Gillian Sadler, Pauline Wood, Rachel Ryan, Claire Ryan, Sandra
Burt and Clare Calvert from the Kent Oncology Centre, Maidstone Hospital.
Thanks are also due to the research teams at the following centres who have randomised
patients to SUPREMO in May [patients in June / total patients recruited to date by site]:
Dr Jackie Clarke, Belfast City Hospital (3/19)
Dr Martin Hogg, Royal Preston Hospital (2/11)
Dr Helen Westenberg, Arnhems Radiotherapeutisch Instituut (1/43)
Dr Nicola Russell, Antoni Van Leeuwenhoekziekenhuis (1/35)
Dr Lisa Barraclough, Macclesfield District General Hospital (1/26)
Professor Ye-xiong Li, Chinese Academy of Medical Sciences, Beijing (1/22)
Dr Blanca Farrus, Clinico Y Provincial De Barcelona (1/21)
Dr Charles Lowdell, Charing Cross Hospital (1/15)
Dr Astrid Scholten, Leiden University Medical Centre (1/15)
Dr Scott Carruthers, Royal Adelaide Hospital (1/12)
Dr John Henry Maduro, University Medical Centre, Groningen (1/12)
Dr Sunil Upadhyay, Castle Hill Hospital, Hull (1/11)
Dr Marie-Pierre Sunyach, Centre Leon Berard (1/9)
Dr Peter Simmonds, Southampton General Hospital (1/8)
Dr Peter Barrett-Lee, Velindre Cancer Centre (1/8)
Dr Rajaram Sripadam, Whiston Hospital, St. Helen’s (1/8)
Dr G Truc, Centre Georges-Francois-Leclerc (1/7)
Dr John Hardman, Darlington Memorial Hospital (1/7)
Dr John Hardman, James Cook University Hospital (1/6)
Dr Neil Bayman, Wigan Royal Albert Edward Infirmary (1/6)
Dr Apurna Jegannathen, Staffordshire General Hospital (1/5)
Dr Nicky Thorp, Clatterbridge Centre for Oncology (1/4)
Dr Fiona Roberts, Mid Yorkshire Hospitals NHS Trust (1/3)
Dr Paul Dyson, Cumberland Infirmary (1/2)
Dr Urs Meier, Kantonsspital Winterthur (1/2)
1122 patients have now been randomised to the trial and we would like to thank you
for your continued support for the trial during 2011.
With kind regards,
Professor Ian Kunkler
Chief Investigator, MRC/EORTC SUPREMO trial